Patients Face New Barriers for GLP-1 Drugs Like Wegovy and Ozempic
Even With Lower Prices, Medicare, Medicaid, and Other Insurers Tighten Coverage for Drugs Like Mounjaro and Zepbound Using Prior Authorization and Other Tools
In Their Own Words
The following excerpt is from an op-ed that first appeared in The Kansas City Star on October 12, 2025.
As a nurse and researcher who specializes in pregnancies complicated by fetal conditions, I’ve spent 16 years studying what happens when prenatal testing reveals a potential physical or developmental disability. And here’s what most people don’t expect: Policies that limit abortion after a certain number of weeks can actually push families toward ending a pregnancy. Families facing an unexpected diagnosis are often overwhelmed, uncertain and still learning what it even means. They need time. Time to understand. Time to recalibrate hope. Time to weigh what they can carry — for themselves and their child.
Yet that’s precisely what abortion restrictions rob them of.
Missouri is now at a pivotal crossroads. After voters passed a landmark amendment in 2024 restoring abortion rights up to viability (24 to 26 weeks), the state became the first in the nation to overturn its near-total ban. But access remains limited and under threat. Procedural care is scarce, and a new proposed amendment would repeal those protections and replace them with one of the most restrictive abortion laws in the country, banning abortion in most cases after 12 weeks.
For Missouri families receiving complex prenatal diagnoses, these shifting policies raise urgent questions: Will care be available? Will they have enough time to make informed decisions?
Read the full op-ed here.

Even With Lower Prices, Medicare, Medicaid, and Other Insurers Tighten Coverage for Drugs Like Mounjaro and Zepbound Using Prior Authorization and Other Tools
A 2024 Study Showing How Even Small Copays Reduce PrEP Use Fueled Media, Legal, and Advocacy Efforts As Courts Weighed a Case Threatening No-Cost Preventive Care for Millions
Chart of the Day: LDI Researchers Report Major Coverage Differences Across ACA and Medicaid Plans, Affecting Access to Drugs That Treat Chemo-Related Nausea
Insurers Avoid Counties With Small Populations and Poor Health but a New LDI Study Finds Limited Evidence of Anticompetitive Behavior
A Proven, Low-Risk Treatment Is Backed by Major Studies and Patient Demand, Yet Medicare and Insurers Still Make It Hard To Use
Chart of the Day: Medicare-Medicaid Plans—Created to Streamline Care for Dually Eligible Individuals—Failed to Increase Medicaid Participation in High-Poverty Communities